FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1508308889> ?p ?o ?g. }

• W1508308889 abstract "Background Mucopolysaccharidosis II, also known as Hunter syndrome, is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme iduronate‐2‐sulfatase, which catalyses a step in the catabolism of glycosaminoglycans. The glycosaminoglycans accumulate within tissues affecting multiple organs and physiologic systems. The clinical manifestations include neurologic involvement, severe airways obstruction, skeletal deformities and cardiomyopathy. The disease has a variable age of onset and variable rate of progression. In those with severe disease, death usually occurs in the second decade of life, whereas those individuals with less severe disease may survive into adulthood. Enzyme replacement therapy with intravenous infusions of idursulfase has emerged as a new treatment for mucopolysaccharidosis type II. This is an update of a previously published version of this review. Objectives To evaluate the effectiveness and safety of enzyme replacement therapy with idursulfase compared to other interventions, placebo or no intervention, for treating mucopolysaccharidosis type II. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register (date of last search 23 November 2015). We also searched Embase, PubMed and the Literature Latino‐Americana e do Caribe em Ciências da Saúde (LILACS) (date of last search 28 November 2015). Selection criteria Randomised and quasi‐randomised controlled trials of enzyme replacement therapy with idursulfase compared to no intervention, placebo or other options (e.g. behavioral strategies, transplantation). Data collection and analysis Two authors independently screened the trials identified, appraised quality of papers and extracted data. Main results One study (96 male participants) met the inclusion criteria, although the primary outcome of this review ‐ z score for height and weight, was not assessed in the study. This trial was considered to be of overall good quality. Following 53 weeks of treatment, participants in the weekly idursulfase 0.5 mg/kg group demonstrated a significant improvement rate compared with placebo for the primary outcome: distance walked in six minutes on the basis of the sum of ranks of change from baseline, mean difference 37.00 (95% confidence interval 6.52 to 67.48). The every‐other‐week idursulfase 0.5 mg/kg group also showed an improvement, which was not significant compared with placebo, mean difference 23.00 (95% confidence interval ‐4.49 to 50.49). After 53 weeks, there was no statistical significance difference in per cent predicted forced vital capacity between the three groups and absolute forced vital capacity was significantly increased from baseline in the weekly dosing group compared to placebo, mean difference 0.16 (95% confidence interval CI 0.05 to 0.27). No difference was observed between the every‐other‐week idursulfase 0.5 mg/kg group and placebo. In addition, liver and spleen volumes and urine glycosaminoglycan excretion were significantly reduced from baseline by both idursulfase dosing regimens. Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of participants at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. Authors' conclusions The current evidence is limited. While the randomised clinical trial identified was considered to be of good quality, it failed to describe important outcomes. It has been demonstrated that enzyme replacement therapy with idursulfase is effective in relation to functional capacity (distance walked in six minutes and forced vital capacity), liver and spleen volumes and urine glycosaminoglycan excretion in people with mucopolysaccharidosis type II compared with placebo. There is no available evidence in the included study and in the literature on outcomes such as improvement in growth, sleep apnoea, cardiac function, quality of life and mortality. More studies are needed to obtain more information on the long‐term effectiveness and safety of enzyme replacement therapy." @default.
• W1508308889 created "2016-06-24" @default.
• W1508308889 creator A5000968202 @default.
• W1508308889 creator A5005564989 @default.
• W1508308889 creator A5018061572 @default.
• W1508308889 creator A5065598597 @default.
• W1508308889 date "2016-02-05" @default.
• W1508308889 modified "2023-09-30" @default.
• W1508308889 title "Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)" @default.
• W1508308889 cites W1989295722 @default.
• W1508308889 cites W1993027304 @default.
• W1508308889 cites W1997831257 @default.
• W1508308889 cites W2000685247 @default.
• W1508308889 cites W2002512312 @default.
• W1508308889 cites W2020409398 @default.
• W1508308889 cites W2021041107 @default.
• W1508308889 cites W2026723102 @default.
• W1508308889 cites W2034511507 @default.
• W1508308889 cites W2092327321 @default.
• W1508308889 cites W2093722439 @default.
• W1508308889 cites W2117500144 @default.
• W1508308889 cites W2125435699 @default.
• W1508308889 cites W2127736061 @default.
• W1508308889 cites W2130235475 @default.
• W1508308889 cites W2137730372 @default.
• W1508308889 cites W2148045371 @default.
• W1508308889 cites W2149588051 @default.
• W1508308889 cites W2165934664 @default.
• W1508308889 cites W3145867599 @default.
• W1508308889 cites W4231294703 @default.
• W1508308889 cites W4237236619 @default.
• W1508308889 cites W4245666729 @default.
• W1508308889 doi "https://doi.org/10.1002/14651858.cd008185.pub4" @default.
• W1508308889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7173756" @default.
• W1508308889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26845288" @default.
• W1508308889 hasPublicationYear "2016" @default.
• W1508308889 type Work @default.
• W1508308889 sameAs 1508308889 @default.
• W1508308889 citedByCount "34" @default.
• W1508308889 countsByYear W15083088892013 @default.
• W1508308889 countsByYear W15083088892014 @default.
• W1508308889 countsByYear W15083088892015 @default.
• W1508308889 countsByYear W15083088892016 @default.
• W1508308889 countsByYear W15083088892017 @default.
• W1508308889 countsByYear W15083088892018 @default.
• W1508308889 countsByYear W15083088892019 @default.
• W1508308889 countsByYear W15083088892020 @default.
• W1508308889 countsByYear W15083088892021 @default.
• W1508308889 countsByYear W15083088892022 @default.
• W1508308889 countsByYear W15083088892023 @default.
• W1508308889 crossrefType "journal-article" @default.
• W1508308889 hasAuthorship W1508308889A5000968202 @default.
• W1508308889 hasAuthorship W1508308889A5005564989 @default.
• W1508308889 hasAuthorship W1508308889A5018061572 @default.
• W1508308889 hasAuthorship W1508308889A5065598597 @default.
• W1508308889 hasBestOaLocation W15083088892 @default.
• W1508308889 hasConcept C126322002 @default.
• W1508308889 hasConcept C142724271 @default.
• W1508308889 hasConcept C187212893 @default.
• W1508308889 hasConcept C204787440 @default.
• W1508308889 hasConcept C27081682 @default.
• W1508308889 hasConcept C2776225084 @default.
• W1508308889 hasConcept C2779134260 @default.
• W1508308889 hasConcept C2779416428 @default.
• W1508308889 hasConcept C2779969927 @default.
• W1508308889 hasConcept C2910638406 @default.
• W1508308889 hasConcept C2910727661 @default.
• W1508308889 hasConcept C71924100 @default.
• W1508308889 hasConceptScore W1508308889C126322002 @default.
• W1508308889 hasConceptScore W1508308889C142724271 @default.
• W1508308889 hasConceptScore W1508308889C187212893 @default.
• W1508308889 hasConceptScore W1508308889C204787440 @default.
• W1508308889 hasConceptScore W1508308889C27081682 @default.
• W1508308889 hasConceptScore W1508308889C2776225084 @default.
• W1508308889 hasConceptScore W1508308889C2779134260 @default.
• W1508308889 hasConceptScore W1508308889C2779416428 @default.
• W1508308889 hasConceptScore W1508308889C2779969927 @default.
• W1508308889 hasConceptScore W1508308889C2910638406 @default.
• W1508308889 hasConceptScore W1508308889C2910727661 @default.
• W1508308889 hasConceptScore W1508308889C71924100 @default.
• W1508308889 hasIssue "2" @default.
• W1508308889 hasLocation W15083088891 @default.
• W1508308889 hasLocation W15083088892 @default.
• W1508308889 hasLocation W15083088893 @default.
• W1508308889 hasLocation W15083088894 @default.
• W1508308889 hasOpenAccess W1508308889 @default.
• W1508308889 hasPrimaryLocation W15083088891 @default.
• W1508308889 hasRelatedWork W1508308889 @default.
• W1508308889 hasRelatedWork W1572142576 @default.
• W1508308889 hasRelatedWork W1584581471 @default.
• W1508308889 hasRelatedWork W2034511507 @default.
• W1508308889 hasRelatedWork W2276056773 @default.
• W1508308889 hasRelatedWork W2335333758 @default.
• W1508308889 hasRelatedWork W3047459082 @default.
• W1508308889 hasRelatedWork W3082276934 @default.
• W1508308889 hasRelatedWork W4283362395 @default.
• W1508308889 hasRelatedWork W820401292 @default.
• W1508308889 hasVolume "2016" @default.
• W1508308889 isParatext "false" @default.
• W1508308889 isRetracted "false" @default.

• next